New Single-Shot drug may protect kids on chemo from dangerous infections
NCT ID NCT06926751
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a single injection of Telpegfilgrastim works better than daily Filgrastim shots to prevent fever and low white blood cells in children and young adults (ages 6-24) with solid tumors receiving strong chemotherapy. About 132 participants will receive either drug after each chemo cycle and be monitored for infections, side effects, and treatment delays. The goal is to find a safer, more convenient way to manage chemotherapy side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADOLESCENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden heart risks in Wilson's disease: a new scan could spot them early
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Ear acupressure: a new weapon against chemotherapy side effects?
- Can a new drug outperform standard care for a rare liver disease in teens?
- Can a new formula save more children from severe malnutrition?